Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-07
2006-11-07
Desai, Rita (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S292000, C514S269000, C546S082000
Reexamination Certificate
active
07132428
ABSTRACT:
Compounds of the formula Iare suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
REFERENCES:
patent: 4748246 (1988-05-01), Skotnicki et al.
patent: 6841556 (2005-01-01), Flohr et al.
patent: 1134221 (2001-09-01), None
patent: 2185255 (1987-07-01), None
patent: WO 02/44153 (2002-06-01), None
patent: WO 03/024936 (2003-03-01), None
Yumi Yamamoto et al., Role of the NF-kB Pathway in the Pathogenesis of Human Disease States, Current Molecullar Medicine (2001, pp. 287-296, vol. 1).
Lucia Cecchi et al., Synthesis of 1,5-Diaryl-3-Methyl-1 H-pyrazolo(4,5-c) Isoquinolines And Studies of Binding to Specific Peripheral Benzodiazepine Binding Sites, Journal of Pharmaceutical Sciences (1989, pp. 437-442, vol. 78, No. 6).
Collar Nicola
Hopkins Corey
Majid Tahir Nadeem
Merrill Jean
Pedgrift Brian Leslie
Aventis Pharmaceuticals Inc.
Desai Rita
Gupta Balaram
LandOfFree
Pyrazoloisoquinoline derivative as kinase inhibitors for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazoloisoquinoline derivative as kinase inhibitors for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazoloisoquinoline derivative as kinase inhibitors for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3643047